アレルギー性疾患の新治療剤 MS 抗原に関する臨床的研究

概要

論文の詳細を見る
In 1965, an antigenic substance was extracted from patient's urine suffering for allergic diseases (Soeda). This substance was named MS-antigen, and it is now obtained in an amorphous and powdery form. It is almost non-toxic and can induce production of precipitin when inoculated into man and animals. It was experimentally shown that serum titers of precipitin are rapidly enhanced by its repeated injection and maintained for fairly a long period after its administration is discontinued, and that allergic manifestations are almost completely suppressed as far as serum titers of precipitin are maintained significantly high. We have treated patients with various allergic diseases with MS-antigen and achieved fairly excellent results as follows: 1. Total 62 patients with allergic rhinitis were treated and excellent therapeutic results were achieved in 46 cases (74.2%) of the cases and 11 cases (17.7%) good response. 2. Total 38 patients with skin lesions were treated and excellent therapeutic results were achieved in 32 cases (84%) and 3 cases (7.9%) good results. 3. Total 30 patients with asthma bronchial were treated with MS-antigen, and now 20 patients are completely well, while 7 cases have been much improved. The remaining 3 cases did not respond to this therapy, except for temporal improvement. 4. 2 patients with rheumatoid arthritis (acute exacerbation) were treated and excellent therapeutic results and no recurrence for about 14 months. There appears to exist at least two types in MS-antigen, A and B, and accordingly patients with allergic diseases may be divided into A and B groups depending upon their serum response to either type of MS-antigen. The serum titers of precipitin should be maintained high to inhibit recurrence of allergic diseases.
日本アレルギー学会の論文
1967-09-30

アレルギー性疾患の新治療剤 MS 抗原に関する臨床的研究

スポンサーリンク

概要

著者

関連論文

スポンサーリンク